News

Under the agreement, Healthscreen will provide a range of important clinical measurements to Sanofi-aventis to offer assistance in research activities. Healthscreen said that the partnership will assist the

The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening apps. It allows researchers to run 1 to

The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.

The unique identifier codes will be applied to several Unichem medicines, including Trika for the treatment of anxiety and Losar for the treatment of high blood pressure and

Provectus Pharma expects to recruit up to 90 subjects at four different sites in Phase 2c study, in late December. In the trial, the subjects will be randomised

IXO Therapeutics is a start-up from the Natural Environment Research Council (NERC) and will focus on developing intellectual property (IP) derived from both NERC and the University of

The circumsporozoite protein (CSP) has been identified as a potential target in the development of vaccines focused on the earlier stages of malaria infection. The researchers are working

Novartis Pharma and Aventis, who have been involved in legal dispute over rights of anti-rabies vaccine Rabipur, have agreed to settle their dispute following the transaction. Until February

Zerhouni will report directly to Christopher Viehbacher, CEO of Sanofi-aventis, and join the executive committee and the management committee. Sanofi-aventis said that since Zerhouni appointment as scientific advisor